CF PHARMTECH (02652) saw a nearly 3% increase this morning, with a current rise of 2.74%, trading at HKD 29.20 and a transaction volume of HKD 5.3645 million. According to official news from CF PHARMTECH, the company’s self-developed bronchial valve lung volume reduction device has successfully completed its first participant enrollment (FPI), marking the official start of the clinical validation phase aimed at expanding minimally invasive treatment options for patients with emphysema and other chronic obstructive pulmonary disease (COPD) conditions. The smooth completion of the initial enrollment surgery signifies that this innovative minimally invasive device has officially entered the clinical validation stage. It is noted that patients with emphysema often experience dynamic hyperinflation and limited mobility, and existing therapies have significant unmet clinical needs in achieving long-term management and substantial improvement in quality of life. This human trial device utilizes bronchoscopic airflow control at the branch level and targeted lung region reduction strategies, aiming to reduce residual volume (RV) while improving lung function and exercise tolerance, and enhancing reproducibility and post-operative management controllability based on individualized assessment. The study will continue with planned participant enrollment, perioperative safety monitoring, and multidimensional imaging/pulmonary function assessments, focusing on safety related to the device and operation as well as technical success rates, while observing trends in key clinical outcomes like FEV1, RV, 6MWD, and SGRQ. The research data will create an auditable evidence chain for subsequent registration strategies and commercialization decisions.